Mao Yi-An, Wang Rui, Shi Xiaozhou, Jin Yanjia, Pan Zihan, Chatterjee Emeli, Li Guoping, Chen Xuerui, Wang Hongdong, Jiang Jizong, Xiao Junjie
Joint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Cardiac Regeneration and Ageing Lab, School of Life Science, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.
J Cardiovasc Transl Res. 2025 Jul 18. doi: 10.1007/s12265-025-10660-9.
Myocardial infarction (MI), is a leading cause of global mortality, marked by cardiomyocyte death. This takes place as a result of ischemic injury, the detrimental impacts of oxidative stress, and inflammatory responses. Conventiona pharmacological interventions, are unfortunately limited by a relatively low targeting efficiency and the inability to reverse the fate of cardiomyocyte death. Recent advances in nanotechnology have led to the development of multifunctional nanoparticles, offering innovative solutions to effectively address these complex challenges. These nanoscale platforms have the remarkable capability to enable targeted drug delivery, precisely regulate the microenvironment, and facilitate real-time monitoring of the cardiac repair processes. This development represents a substantial paradigm shift in the treatment of MI. This review integrates the crucial findings obtained from the recent studies focusing on nanoparticle-based strategies for multifunctional cardiac repair after MI, aiming to explore the potential of nanoparticles in the treatment of MI.
心肌梗死(MI)是全球死亡的主要原因,其特征是心肌细胞死亡。这是由于缺血性损伤、氧化应激的有害影响和炎症反应所致。不幸的是,传统的药物干预受到相对较低的靶向效率以及无法逆转心肌细胞死亡命运的限制。纳米技术的最新进展已导致多功能纳米颗粒的开发,为有效应对这些复杂挑战提供了创新解决方案。这些纳米级平台具有显著的能力,能够实现靶向药物递送、精确调节微环境并促进心脏修复过程的实时监测。这一进展代表了心肌梗死治疗的重大范式转变。本综述整合了近期研究中关于基于纳米颗粒的心肌梗死后多功能心脏修复策略的关键发现,旨在探索纳米颗粒在心肌梗死治疗中的潜力。
J Cardiovasc Transl Res. 2025-7-18
Neural Regen Res. 2025-6-19
Cochrane Database Syst Rev. 2017-4-28
Cochrane Database Syst Rev. 2016-5-26
Cochrane Database Syst Rev. 2000
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-11-6
Health Technol Assess. 2007-4
Cochrane Database Syst Rev. 2016-1-5
Nat Med. 2025-1
Circulation. 2025-1-21